Submit comments on final section of AD guidelines covering prevention of disease flares and use of adjunctive approaches

               

By Lawrence F. Eichenfield, MD

The Academy requests your feedback for part four of the atopic dermatitis guidelines, the final section in this comprehensive update.

This guideline covers important information related to the management and control of AD flares using topical modalities, the utility and timing of allergen testing and avoidance, and the use of adjunctive therapies and approaches in the management of this condition. 

From Feb. 28 through March 13, part four will be available for review on the Academy website. If you would like to comment on the guideline, you will need to follow three steps:

  1. Be sure you have a current conflict of interest disclosure statement on record with the Academy.
  2. Review the draft guideline here.
  3. Email your comments to guidelines@aad.org.

These guidelines were last published in 2004, and since that time, a great deal of research has been published on AD. Together with my co-chair, Robert Sidbury, MD, and group of dedicated colleagues, we have thoroughly analyzed the new data to develop updated and expanded recommendations for the diagnosis, assessment, and treatment of AD.

Your input has been very valuable in the creation of this important guideline series. We look forward to hearing your comments on part four.

Dr. Eichenfield is chief of pediatric and adolescent dermatology at Rady Children's Hospital, San Diego, and at the University of California, San Diego School of Medicine. He also is professor of clinical pediatrics and medicine (dermatology) at the university.

                AAD Logo 

Related resources from AAD.org:

M2M logo 

Related resources from Member to Member: